FDA warns UK online seller Alwinshop that its "Prostatitis Remission Cream" is an unapproved, misbranded drug with false FDA endorsement claims.
What happened
FDA reviewed the company's website (alwinshop.com) and TikTok shop in May 2026 rather than conducting an inspection. FDA found labeling claims such as "Improved Bladder Control," "Better Bladder Emptying," and "Treatment for Prostatitis Symptom Relief," which make the cream a drug intended to treat disease. FDA also found the site used an image of FDA officials and an FDA logo plus a statement about "FDA certification," which falsely suggest FDA approved or endorsed the product.
What FDA found
The cream is a drug because its labeling claims it treats disease and affects how the body works.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)It is a new drug with no FDA-approved application, so it cannot legally be sold across state lines.
Sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d)The labeling is false or misleading because it uses an FDA logo and a photo of FDA officials, suggesting FDA endorsement.
Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)The claim that "FDA certification" means the product met the highest safety and effectiveness standards is misleading, since FDA never approved or endorsed it.
Section 502(a) of the FD&C Act, 21 U.S.C. 352(a)Shipping a misbranded drug across state lines is prohibited.
Section 301(a) of the FD&C Act, 21 U.S.C. 331(a)
What FDA wants
FDA tells the company to reply in writing to FDAAdvisory@fda.hhs.gov within 15 business days of receiving the letter, listing the specific corrections made, steps to prevent repeat violations, and supporting documents, with reference number 729062 in the subject line.
Who should pay attention
- online sellers and TikTok Shop merchants of health creams and supplements
- marketers who use FDA logos, images, or "FDA certification" wording
- brands making disease-treatment claims for cosmetic or personal-care products
This is a summary. Read the original letter on fda.gov.